Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Sarcoma 1Other solid neoplasm 1NET 1Head & Neck 1Genitourinary 1Endocrine 1Breast 1

Conditions

Colorectal Neoplasms 62Carcinoma, Hepatocellular 25Neoplasm Metastasis 15Rectal Neoplasms 11Colonic Neoplasms 10Gastrointestinal Stromal Tumors 9Sarcoma 6Ovarian Neoplasms 5Osteosarcoma 5Glioblastoma 5Cholangiocarcinoma 5Stomach Neoplasms 4Melanoma 4Liver Neoplasms 4Sarcoma, Ewing 3Pancreatic Neoplasms 3Neoplasms 3Leukemia, Myeloid, Acute 3Esophageal Neoplasms 3Colorectal Cancer Metastatic 3Carcinoma, Non-Small-Cell Lung 3Thyroid Neoplasms 2Rhabdomyosarcoma 2Myelodysplastic Syndromes 2Multiple Myeloma 2Mesothelioma, Malignant 2Lymphoma, Non-Hodgkin 2Hematologic Neoplasms 2Hemangiosarcoma 2Gastrointestinal Neoplasms 2

Interventions

Gemcitabine 58Cisplatin 41Capecitabine 27Oxaliplatin 25durvalumab 16Fluorouracil 16Leucovorin 15S 1 (combination) 11lenvatinib 10Nivolumab 10Irinotecan 10pembrolizumab 8apatinib 8Immune Checkpoint Inhibitors 7130-nm albumin-bound paclitaxel 7tremelimumab 6Bevacizumab 6camrelizumab 5Trastuzumab 5Drug Therapy 5Blood Specimen Collection 5Albumin-Bound Paclitaxel 5tislelizumab 4irinotecan sucrosofate 4Taxes 4Liquid Biopsy 4Folfox protocol 4toripalimab 3surufatinib 3gemcitabine-oxaliplatin regimen 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Biliary Tract Neoplasms × regorafenib × Clear all
NCT03475953 2023-03-03

REGOMUNE

Institut Bergonié

Phase 1/2 Unknown
747 enrolled
BreastEndocrineGastrointestinalGenitourinaryHead & NeckNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Turcot syndrome, Tertiary Lymphoid Structures, Mesothelioma, Malignant, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Triple Negative Breast Neoplasms

NCT02053376 2019-01-30

A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy

University of Pittsburgh

Phase 2 Completed
43 enrolled 15 charts
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡